Munenobu Kashiwa

8PUBLICATIONS
0CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Pacific Peoples life courseEconomic models and forecastingToxicology (incl. clinical toxicology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Sep 28, 2026
Healthcare Cost Patterns in CDK4/6 Inhibitor-Treated HR+/HER2- Metastatic Breast Cancer.

|May 28, 2026
Difference in Cost-Effectiveness of Trastuzumab Deruxtecan in First-Line Versus Later-Line Settings for HER2-Low Metastatic Breast Cancer.

|May 13, 2026
Economic Burden of Cachexia in Japanese Lung Cancer Patients: A Retrospective Claims Database Analysis.

|Sep 21, 2024
Comparative Cost-Effectiveness of Atezolizumab Versus Durvalumab as First-Line Combination Treatment with Chemotherapy for Patients with Extensive-Disease Small-Cell Lung Cancer in Japan.

Munenobu Kashiwa, Miho Tsukada, Ryo Matsushita

|Jun 01, 2023
Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan.

Munenobu Kashiwa

|Apr 20, 2023
Model-based cost-utility analysis of gemcitabine, cisplatin, and S-1 as triple therapy for advanced biliary tract cancer.

Munenobu Kashiwa, Ryo Matsushita

Pageof 2

Frequent Collaborators